MiNK Therapeutics, Inc.

NASDAQ:INKT

Biotechnology

Healthcare
$10.22 -2.87%

-$0.35 today

Market cap
$52.17M
Beta
0.47
P/E (TTM)
-4.6
EPS (TTM)
-$2.60
52W Low $6.80High $76.00

Volume 0.01M

Average 0.05M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$12.49M

FY 2025 · Annual

Net Income

-$12.49M

FY 2025 · Annual

Income Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Revenue00000
Cost of Revenue77.96K121.75K204.62K215.44K181.75K
Gross Profit(77.96K)(121.75K)(204.62K)(215.44K)(181.75K)
Gross Margin—————
Research & Development13.97M23.12M15.49M6.34M5.76B
Selling, General & Admin4.56M7.71M7.43M4.1M6.73B
Operating Expenses18.53M30.83M22.72M10.43M12.31M
Depreciation & Amortization77.96K121.75K204.62K215.44K181.75K
EBITDA(27.7M)(27.87M)(22.25M)(10.57M)(12.31M)
EBITDA Margin—————
Operating Income(18.61M)(30.95M)(22.92M)(10.65M)(12.49M)
Operating Margin—————
Interest Income2.43K253.32K463.26K172.57K180.25K
Interest Expense2.43M253.32K000
Other Income / Expenses(11.61M)2.96M463.25K(134.56K)(6.96K)
Income Before Tax(30.21M)(27.99M)(22.46M)(10.78M)(12.49M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(30.21M)(27.99M)(22.46M)(10.78M)(12.49M)
Net Margin—————
EPS (Basic)(9.03)(8.31)(6.54)(2.90)(2.93)
EPS (Diluted)(9.03)(8.31)(6.54)(2.80)(2.93)
Weighted Avg Shares3.35M3.37M3.44M3.74M4.27M
Weighted Avg Shares (Diluted)3.35M3.37M3.44M3.86M4.27M

INKT Earnings Waterfall · TTM

NASDAQ:INKT · Revenue to Net Income

Key Ratios

EPS$-2.83
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-4.1
P/S Ratio0.0

Analysis

$0 of revenue converted into -$12.5M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.83, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipOct 14, 2026
4Statement of changes in beneficial ownershipSep 2, 2026
4Statement of changes in beneficial ownershipSep 2, 2026
4Statement of changes in beneficial ownershipSep 2, 2026
4Statement of changes in beneficial ownershipSep 2, 2026

How much revenue does INKT generate?

MiNK Therapeutics, Inc. (INKT) reported $0.00 of revenue in fiscal 2025.

Is INKT profitable?

MiNK Therapeutics, Inc. (INKT) reported -$12.49M of net income.